EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models

Elisabetta Puliga iD, Chiara De Bellis, Sandra Vietti Michelina, Tania Capeloa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid, Uberto Fumagalli Romario, Chiara Ambrogio und 2 weitere

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01468-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Elisabetta Puliga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Torino, Candiolo, Italy. elisabetta.puliga@ircc.it. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a poor prognosis for patients with advanced disease. Since the oncogenic role of KRAS mutants has been poorly investigated in GC, this study aims to biochemically and biologically characterize different KRAS-mutated models and unravel differences among KRAS mutants in response to therapy.

Methods

Taking advantage of a proprietary, molecularly annotated platform of more than 200 GC PDXs (patient-derived xenografts), we identified KRAS-mutated PDXs, from which primary cell lines were established. The different mutants were challenged with KRAS downstream inhibitors in in vitro and in vivo experiments.

Results

Cells expressing the rare KRAS A146T mutant showed lower RAS-GTP levels compared to those bearing the canonical G12/13D mutations. Nevertheless, all the KRAS-mutated cells displayed KRAS addiction. Surprisingly, even if the GEF SOS1 is considered critical for the activation of KRAS A146T mutants, its abrogation did not significantly affect cell viability. From the pharmacologic point of view, Trametinib monotherapy was more effective in A146T than in G12D -mutated models, suggesting a vulnerability to MEK inhibition. However, in the presence of mutations in the PI3K pathway, more frequently co-occurrent in A146T models, the association of Trametinib and the AKT inhibitor MK-2206 was required to optimize the response.

Conclusion

A deeper genomic and biological characterization of KRAS mutants might sustain the development of more efficient and long-lasting therapeutic options for patients harbouring KRAS -driven GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesMutationProtein Kinase InhibitorsCell Line, Tumor

Stichwörter der Autor:innen

KRAS mutantsGastric cancerOncogene addictionRAS downstream signalling

Substanzen

Proto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsKRAS protein, human

Autor:innen und Institutionen

  • Department of Oncology, University of Torino, Candiolo, Italy. elisabetta.puliga@ircc.it.
  • Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. elisabetta.puliga@ircc.it.
  • Department of Oncology, University of Torino, Candiolo, Italy.
  • Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Turin, Italy.
  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

ORCID-Profile: Elisabetta Puliga

Förderung

  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

Puliga, E., De Bellis, C., Vietti Michelina, S., Capeloa, T., Migliore, C., Orrù, C., Baiocchi, G. L., De Manzoni, G., Pietrantonio, F., Reddavid, R., Fumagalli Romario, U., Ambrogio, C., Corso, S., & Giordano, S. (2024). Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Gastric Cancer. https://doi.org/10.1007/s10120-024-01468-8

Vancouver

Puliga E, De Bellis C, Vietti Michelina S, Capeloa T, Migliore C, Orrù C, et al. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Gastric Cancer. 2024. doi:10.1007/s10120-024-01468-8

BibTeX
@article{Puliga2024,
  author = {Puliga, Elisabetta and De Bellis, Chiara and Vietti Michelina, Sandra and Capeloa, Tania and Migliore, Cristina and Orrù, Claudia and Baiocchi, Gian Luca and De Manzoni, Giovanni and Pietrantonio, Filippo and Reddavid, Rossella and Fumagalli Romario, Uberto and Ambrogio, Chiara and Corso, Simona and Giordano, Silvia},
  title = {Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01468-8}
}
Kostenlos starten →